Treatment of Permeability Failure

Description: Peritoneal dialysis is used to treat patients having renal failure. The dialysis fluid used in such treatment contains very high levels of glucose, in order to cause the osmotic extraction of toxins from the blood; however, these levels of glucose appear to damage the cells lining the peritoneum, resulting in decreased permeability between the dialysis fluid and the blood. The invention is based on the discovery that protein kinase C (PKC) is responsible for the damaging effects of high glucose in this system. Clinical & Commercial Utility: The invention therefore features the use of inhibitors of PKC, particularly inhibitors specific for this kinase, to prevent the damaging effects of glucose in patients undergoing dialysis over long periods of time. The inhibitor may be active against the beta, gamma or delta forms of PKC. The inhibitor is included within the dialysis fluid, and is continuously administered via this fluid.
Joslin Diabetes Center is the owner of U.S. Patent Number 6,753,341 claiming this invention.

Type of Offer: Licensing



« More Medical Patents

---